Inpatient allergy/immunology consultations in a tertiary care setting.
Few studies have examined inpatient referral patterns for fellowship training programs and none for allergy/immunology (AI) since 2003. The primary end point was the reason for consultation, and secondary end points included the AI diagnosis made and outcomes. We retrospectively reviewed all inpatient AI consultations from July 1, 2001 through June 30, 2007. These 6 years of data were combined with 14 years of data examining the reason for consult from a previous study. The data were analyzed for trends and changes over the entire 20-year period. A total of 254 AI inpatient consults were reviewed over the 6 years studied. Thirty-six percent (92/254) of inpatient consults were for evaluation of adverse drug reactions (ADRs), 22% (55/254) miscellaneous reasons, 17% (43/254) urticaria/angioedema, 13% (32/254) for possible immunodeficiency, 9% (23/254) for anaphylaxis, and 3% (8/254) for asthma. AI inpatient consults show a significant decline over the recent 6-year period (p = 0.0023) despite stable total hospital admissions since 1998. Over the last 20 years, an 85% decrease (p < 0.00001) in inpatient asthma consults and increases (p < 0.05) in immunodeficiency, rash, and urticaria/angioedema evaluations have been observed. Not following AI recommendations resulted in a 16.6 odds ratio (95% CI, 5.55-49.93) that a patient's clinical status would be worse or unchanged. Inpatient AI consults have declined with associated reduction in asthma inpatient consults. Although ADRs and anaphylaxis consults have been stable, evaluations for immunodeficiency, rash, and urticaria/angioedema have increased. Following inpatient AI recommendations is associated with improved patient outcomes.
Otto
Hans F
HF
Department of Allergy and Immunology, Wright Patterson Medical Center, Wright-Patterson Air Force Base, Dayton, Ohio 45433, USA. hans.otto@wpafb.af.mil
England
Ronald W
RW
Quinn
James M
JM
D000486:Allergy and Immunology; D000707:Anaphylaxis; D001249:Asthma / Q000453:epidemiology* / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D004342:Drug Hypersensitivity / Q000453:epidemiology* / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D019983:Guideline Adherence; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000453:epidemiology* / Q000276:immunology / Q000503:physiopathology / Q000628:therapy; D007297:Inpatients; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012189:Retrospective Studies; D055512:Tertiary Prevention / Q000639:trends; D014581:Urticaria